1-Year Tirzepatide, Ixekizumab Combo Trial Results Reported
Eli Lilly reported 1-year results from two phase 3b trials showing that a combination of ixekizumab (Taltz) and tirzepatide (Zepbound) significantly improved disease activity in patients with psoriasis or psoriatic arthritis compared to ixekizumab alone. The trials also showed improvements in weight loss, inflammation, and metabolic markers. According to Eli Lilly, the combination therapy had a favorable safety profile.
How this was made
The 30-second read
Why it matters
The data suggest a new therapeutic avenue that could expand Lilly's product portfolio and drive revenue growth.
Market read
First‑time positive Phase 3b results could move Eli Lilly stock and influence biotech sector sentiment.
What to watch
pricing, insurance coverage, and competition from other GLP‑1 combos could limit upside.
Background
Eli Lilly funded two open‑label Phase 3b trials (TOGETHER‑PsO and TOGETHER‑PsA) to evaluate tirzepatide with ixekizumab in patients with psoriasis or psoriatic arthritis and obesity.
Ticker impact
Eli Lilly announced 1‑year Phase 3b trial results for the tirzepatide + ixekizumab combo, showing significant efficacy over ixekizumab alone.
upward pressure as investors price in potential label expansion and additional revenue streams.
First‑time disclosure of statistically significant outcomes in a large Phase 3b study for a dual‑therapy approach.
Market effects
could spur interest in combination therapies for obesity‑related inflammatory diseases.
U.S. biotech sector may see modest gains.
potentially relevant for global pharma pipelines targeting psoriasis and PsA.
Counterpoint
skeptics may question long‑term safety and commercial viability of a dual‑therapy regimen.
Key entities
- companyEli Lilly
Pharmaceutical manufacturer of tirzepatide and ixekizumab.
- drugTirzepatide (Zepbound)
GLP‑1 receptor agonist.
- drugIxekizumab (Taltz)
IL‑17A inhibitor for psoriasis and PsA.
